Zevra Therapeutics Inc [ZVRA] stock is trading at $9.03, up 4.27%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZVRA shares have gain 2.50% over the last week, with a monthly amount glided 6.74%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Zevra Therapeutics Inc [NASDAQ: ZVRA] stock has seen the most recent analyst activity on October 07, 2024, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Maxim Group reaffirmed its Buy rating on September 24, 2024, and elevated its price target to $25. On September 24, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $17 on the stock. Maxim Group reiterated its Buy rating and increased its price target to $18 on April 02, 2024. William Blair initiated its recommendation with a Outperform. Maxim Group started tracking with a Buy rating for this stock on March 17, 2023, and assigned it a price target of $12.
Zevra Therapeutics Inc [ZVRA] stock has fluctuated between $4.11 and $9.09 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $9.03 at the most recent close of the market. An investor can expect a potential return of 132.56% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Zevra Therapeutics Inc [NASDAQ:ZVRA] reported sales of 24.79M for the trailing twelve months, which represents a growth of 27.63%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -3.48%, Pretax Profit Margin comes in at -3.43%, and Net Profit Margin reading is -3.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.6 and Total Capital is -0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.86.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.52 points at the first support level, and at 8.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.38, and for the 2nd resistance point, it is at 9.72.
Ratios To Look Out For
For context, Zevra Therapeutics Inc’s Current Ratio is 2.88. As well, the Quick Ratio is 2.00, while the Cash Ratio is 1.57. Considering the valuation of this stock, the price to sales ratio is 19.17, the price to book ratio is 6.89.
Transactions by insiders
Recent insider trading involved Watton Corey Michael, Director, that happened on Oct 11 ’24 when 500.0 shares were purchased. CFO & Treasurer, Clifton R. LaDuane completed a deal on Jul 17 ’24 to buy 2000.0 shares. Meanwhile, Director Anderson Thomas bought 10000.0 shares on Jul 16 ’24.
